The OPTimization of Interferon for MS study: 375 μg interferon beta-1b in suboptimal responders

Journal of Neurology

Volumn 255, Issue 9, 2008, Pages 1315-1323

  Durelli, L ^a   Barbero, P ^a   Bergui, M ^a   Versino, E ^a   Bassano, M A ^b   Verdun, E ^a   Ferrero, B ^a   Rivoiro, C ^a   Ferrero, C ^a   Picco, E ^a   Ripellino, P ^a   Viglietti, D ^a   Giuliani, G ^c   Montanari, E ^d   Clerico, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Dimensione Ricerca   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d Ospedale Civile   (Italy)

Author keywords

Immunomodulatory drugs; Interferon beta (IFN ); MRI activity; Multiple sclerosis; Suboptimal treatment response

Indexed keywords

INTERFERON BETA SERINE; METHYLPREDNISOLONE; PARACETAMOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 55149115659     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0879-6     Document Type: Article

References (29)

1. Arnason BG for the BEYOND Study Steering Committee (2005) BEYOND - Betaseron®/Betaferon® efficacy yielding outcomes of a new dose. Neurology 62(Suppl 5):A490. Abstract
2. Calabresi 1997 Neurology 48 1446
3. Durelli 2000 J Neurol Sci 178 37
4. Durelli 2002 Lancet 359 1453
5. Files 1998 J Interferon Cytokine Res 18 1019
6. Goodin 2002 Neurology 58 169
7. Goodin 2007 Neurology 68 977
8. Kappos 1999 Lancet 353 964
9. Khan 2001 Mult Scler 7 349
10. Kurtzke 1983 Neurology 33 1444
11. McFarland 1992 Ann Neurol 32 758
12. Morton 2005 J Eval Clin Pract 11 59
13. Panitch 2002 Neurology 59 1496
14. Poser 1983 Ann Neurol 13 227
15. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
16. Pungor 1998 J Interferon Cytokine Res 18 1025
17. Quesada J (1992) Toxicity and side effects of interferons. In: Baron S, Coppenhaver D, Dianzani F (eds) Interferon: principles and medical applications. Galveston, TX: The University of Texas Medical Branch at Galveston Department of Microbiology, pp 427-432
18. Rio 2006 Ann Neurol 59 344
19. Rothuizen 1999 J Neuroimmunol 99 131
20. Rovaris 2003 Am J Neuroradiol 24 75
21. Sorensen 2006 Neurology 67 1681
22. Sormani 1999 J Neurol Sci 163 74
23. Stone 1995 Ann Neurol 37 611
24. Stone 1997 Neurology 49 862
25. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 43:655-661
26. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
27. The Once Weekly Interferon for MS Study Group (1999) Evidence of interferon beta-1a dose response in relapsing- remitting MS: the OWIMS Study. Neurology 53:679-686
28. Tremlett 2003 Neurology 61 551
29. Williams 1998 J Interferon Cytokine Res 18 967